Aileron Therapeutics Inc (ALRN) CFO Buys $16,200.00 in Stock
Aileron Therapeutics Inc (NASDAQ:ALRN) CFO Donald Dougherty acquired 3,000 shares of the stock in a transaction on Friday, June 8th. The shares were purchased at an average price of $5.40 per share, with a total value of $16,200.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Donald Dougherty also recently made the following trade(s):
- On Friday, June 1st, Donald Dougherty acquired 2,000 shares of Aileron Therapeutics stock. The shares were purchased at an average price of $5.24 per share, with a total value of $10,480.00.
Shares of Aileron Therapeutics opened at $5.08 on Wednesday, according to Marketbeat Ratings. Aileron Therapeutics Inc has a one year low of $4.90 and a one year high of $15.48. The company has a market cap of $79.29 million and a price-to-earnings ratio of -2.87.
Separately, ValuEngine upgraded shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $19.33.
A hedge fund recently bought a new stake in Aileron Therapeutics stock. Millennium Management LLC purchased a new position in shares of Aileron Therapeutics Inc (NASDAQ:ALRN) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,585 shares of the company’s stock, valued at approximately $151,000. Millennium Management LLC owned approximately 0.13% of Aileron Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 6.79% of the company’s stock.
About Aileron Therapeutics
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.